Search

Displaying results 2771 - 2780 of 5900 in total
  1. Drug

    Sodium stibogluconate

    go.drugbank.com/drugs/DB05630
    ApprovedInvestigational

    Sodium stibogluconate is a medicine used to treat leishmaniasis and is only available for administration by injection. It belongs to the class of medicines known as the pentavalent antimonials.

  2. Drug

    Proxibarbal

    go.drugbank.com/drugs/DB13253
    Approved

    Proxibarbal is a derivative of barbiturates, which has been used to treat migraines. … Proxibarbal was approved in France but was withdrawn from the market due to the risk of inducing immunoallergic thrombocytopenia [L5476].

  3. Drug

    Sebelipase alfa

    go.drugbank.com/drugs/DB11563
    ApprovedInvestigational

    This lipid accumulation can lead to end-organ damage in the form of liver dysfunction or malabsorption secondary to intestinal dysfunction. … In addition, patients with LAL deficiency typically develop dyslipidemia, which itself contributes to a number of adverse cardiovascular outcomes.

  4. Drug

    Roquinimex

    go.drugbank.com/drugs/DB11366
    Experimental

    Its effects are suggested to increase the activity of NK cells and macrophage cytotoxicity. Additionally, roquinimex is known to inhibit angiogenesis and to decrease the synthesis of TNF alpha.

  5. Drug

    Estradiol benzoate

    go.drugbank.com/drugs/DB13953
    ApprovedVet approvedWithdrawn

    Esterification of estradiol aims to improves absorption and bioavailability after oral administration (such as with Estradiol valerate) or to sustain release from depot intramuscular injections (such as … Ester pro-drugs of estradiol are therefore considered to be bioidentical forms of estrogen [T84]. Estradiol benzoate is not currently available in Canada or the US.

  6. Drug

    Coagulation Factor IX (Recombinant)

    go.drugbank.com/drugs/DB00100
    Approved

    It has a primary amino acid sequence that is identical to the Ala148 allelic form of human factor IX, and has structural and functional characteristics similar to those of endogenous factor IX.

  7. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    Pegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D). … FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction.

    Synonyms: Co-ArgI-PEG, Co-ArgI-PEG modified human arginase I
  8. Drug

    Clioquinol

    go.drugbank.com/drugs/DB04815
    ApprovedVet approvedWithdrawn

    Clioquinol was withdrawn in 1983 due to neurotoxicity.

  9. Drug

    Hexobendine

    go.drugbank.com/drugs/DB13265
    Approved

    Hexobendine is a medication used to cause vasodilation, to treat several conditions including angina pectoris.

  10. Drug

    Hydroxyzine

    go.drugbank.com/drugs/DB00557
    ApprovedInvestigational

    Hydroxyzine is a first-generation histamine H1-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties. It was first developed in 1955, and has since remained a rela...